JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M200732200 on March 14, 2002

J. Biol. Chem., Vol. 277, Issue 22, 19382-19388, May 31, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/22/19382    most recent
M200732200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yu, C. F.
Right arrow Articles by Cantley, L. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yu, C. F.
Right arrow Articles by Cantley, L. G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

ERK Negatively Regulates the Epidermal Growth Factor-mediated Interaction of Gab1 and the Phosphatidylinositol 3-Kinase*

Cheng Fang YuDagger, Zhen-Xiang Liu, and Lloyd G. Cantley

From the Department of Internal Medicine, Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut 06520

Received for publication, January 23, 2002, and in revised form, March 12, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

We have examined the ability of epidermal growth factor (EGF)-stimulated ERK activation to regulate Grb2-associated binder-1 (Gab1)/phosphatidylinositol 3-kinase (PI3K) interactions. Inhibiting ERK activation with the MEK inhibitor U0126 increased the EGF-stimulated association of Gab1 with either full-length glutathione S-transferase-p85 or the p85 C-terminal Src homology 2 (SH2) domain, a result reproduced by co-immunoprecipitation of the native proteins from intact cells. This increased association of Gab1 and the PI3K correlates with an increase in PI3K activity and greater phosphorylation of Akt. This result is in direct contrast to what we have previously reported following HGF stimulation where MEK inhibition decreased the HGF-stimulated association of Gab1 and p85. In support of this divergent effect of ERK on Gab1/PI3K association following HGF and EGF stimulation, U0126 decreased the HGF-stimulated association of p85 and the Gab1 c-Met binding domain but did not alter the EGF-stimulated association of p85 and the c-Met binding domain. An examination of the mechanism of this effect revealed that the treatment of cells with EGF + U0126 increased the tyrosine phosphorylation of Gab1 as well as its association with another SH2-containing protein, SHP2. Furthermore, overexpression of a catalytically inactive form of SHP2 or pretreatment with pervanadate markedly increased EGF-stimulated Gab1 tyrosine phosphorylation. These experiments demonstrate that EGF and HGF-mediated ERK activation result in divergent effects on Gab1/PI3K signaling. HGF-stimulated ERK activation increases the Gab1/PI3K association, whereas EGF-stimulated ERK activation results in a decrease in the tyrosine phosphorylation of Gab1 and a decreased association with the PI3K. SHP2 is shown to associate with and dephosphorylate Gab1, suggesting that EGF-stimulated ERK might act through the regulation of SHP2.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Grb2-associated binder-1 (Gab1)1 has been identified in many cell types and appears to play a central role in multiple cell responses including proliferation, migration, tubulogenesis, cellular transformation, and apoptosis (1-6). Structural and functional studies suggest that Gab1 is a multisubstrate-docking protein functioning downstream of several receptor signaling pathways including the epidermal growth factor (EGF) receptor (EGFR), c-met, and the insulin receptor tyrosine kinases as well as cytokine receptors such as the gp130-associated interleukin-6 receptor and T and B cell antigen receptors (7-10). Similar to the Drosophila daughter of sevenless protein, DOS, and the insulin receptor substrate proteins 1 and 2 family, Gab1 consists of a PH domain at its N terminus, several proline-rich motifs in the C-terminus, and multiple tyrosine phosphorylation sites. But Gab1 is unique in that it contains a c-met binding domain (MBD) that includes the 13 amino acid c-met binding sequence, which mediates direct association with c-met (1, 11). The MBD also mediates indirect association with the activated EGFR via its proline-rich association with the SH3 domain of Grb2 (2, 11, 12). The PH domain has been found to be important for Gab1 localization and epithelial cellular morphogenesis in Madin-Darby canine kidney cells (5), whereas neoplastic transformation in SHE cells has been found to correlate with the loss of this domain (3).

Following ligand binding, Gab1 associates with activated c-met or EGFR and is phosphorylated on specific tyrosine residues, in turn recruiting a series of SH2 domain-containing proteins that initiate intracellular signaling cascades. One of the most important signaling proteins found to associate with Gab1 in response to various stimuli is the phosphoinositide 3-kinase (PI3K). Studies have shown that the activation of the PI3K is involved in a wide range of cellular responses including cell proliferation, differentiation, and prevention of apoptosis (13-15). We have previously demonstrated that the PI3K is required for HGF-mediated kidney epithelial cell migration and in vitro tubulogenesis (16). The importance of Gab1 for this response has been demonstrated in work by Maroun et al. (5) who found that the loss of association of Gab1 and the PI3K due to mutation of the PI3K binding sites in Gab1 results in a decrease of c-met-mediated tubulogenesis in Madin-Darby canine kidney cells. An association of the PI3K with Gab1 was also reported to be required for HGF-mediated cell survival and DNA repair (17).

Previously, it was believed that regulation of the PI3K association with Gab1 was mediated solely by receptor-dependent tyrosine phosphorylation of Gab1 on the PI3K SH2 binding motifs 447YVPM451 and 472YVPM476 in the MBD domain, and/or 589YVPM at the carboxyl terminus. However, we have demonstrated that in addition to tyrosine phosphorylation, Gab1 is also phosphorylated on serine and threonine in response to ERK2 activation by HGF (12). In vitro phosphorylation studies revealed that ERK2 primarily phosphorylates Gab1 in the MBD domain, and an examination of the Gab1 sequence for potential ERK binding and phosphorylation sites revealed that the 476TP478 motif immediately following the 472YVPM476 PI3K binding site was a high probability ERK1/2 phosphorylation site within the MBD domain of Gab1. In a more recent study, we found that the phosphorylation of both Tyr472 and Thr476 resulted in a higher affinity of a YVPMTP-containing peptide for the PI3K than did the phosphorylation of Tyr472 alone. Thus, ERK1/2-mediated phosphorylation of this site can initiate a novel regulation of the Gab1/PI3K interaction. This was confirmed by demonstrating that HGF-stimulated association of the PI3K with Gab1 was partially dependent on ERK activation (7).

Our recent determination that HGF-stimulated epithelial cell morphogenesis requires ERK1/2 activation provides a potential physiologic role for ERK-regulated PI3K activation (18). Interestingly, in this same study, we found that EGF, but not HGF, activates ERK5 in addition to ERK1/2. The expression of a kinase-dead form of ERK5 in epithelial cells prevented EGF-stimulated morphogenesis, demonstrating that EGF and HGF use different MAPK signaling pathways for their morphogenic responses. Because the branching morphogenesis observed following EGF and HGF stimulation is phenotypically distinct, we decided to investigate the effects of EGF-stimulated ERK activation on the association of Gab1 with the PI3K. In contrast to the positive regulation of the Gab1/PI3K interaction that we found following HGF-stimulated ERK activation, EGF-stimulated ERK activation down-regulates the interaction of Gab1 and the PI3K. The investigation of the mechanism of this effect revealed that EGF-stimulated tyrosine phosphorylation of Gab1 was diminished in the setting of ERK activation, thereby decreasing the association of SH2-docking proteins.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Cell Culture and Reagents-- Immortalized mIMCD-3 epithelial cells (19) and HEK cells were maintained at low passage using standard cell culture techniques in Dulbecco's modified Eagle's medium/F-12 containing 10% fetal bovine serum. Experiments were performed when the cells were 80-90% confluent. All reagents were obtained from Sigma unless otherwise noted.

EGF Stimulation and MEK Inhibition-- mIMCD-3 cells were serum-starved for 24 h in Dulbecco's modified Eagle's medium/F-12 and then stimulated with EGF (20 ng/ml, Sigma), HGF (40 ng/ml, Sigma), or vehicle control for 10 min. To inhibit ERK activation, cells were pretreated with 10 µM U0126 (Promega) for 20 min prior to EGF stimulation (7). U0126 has been shown to inhibit MEK1, MEK 2 (20), and MEK5 (18) at concentrations less than 50 µM, but it does not inhibit MEK3, MEK4, MEK6, MEK7, protein kinase Calpha , protein kinase A, PDK1, or other tested serine/threonine kinases (20). U0126 was used rather than PD98059, because we have found that EGF-mediated ERK5 activation, which is critical for EGF-mediated mIMCD-3 cell morphogenesis, is fully inhibited by U0126 but only partially inhibited by PD98059 at concentrations <= 100 µM (18). Following EGF stimulation, cells were lysed in 800 µl of ice-cold radioimmune precipitation lysis buffer containing 50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 2 µg/ml aprotinin, 2 µg/ml leupeptin, 2 µg/ml pepstatin A, 10 mM NaF, 1 mM phenylmethylsulfonyl fluoride, and 1 mM Na3VO4.

GST Fusion Protein Expression and Pull-down Assay-- The GST-p85 full-length N-terminal and C-terminal fusion proteins were expressed as described previously (7, 12). The bacteria were lysed with sodium deoxycholate, and the supernatants were collected and incubated with a 50% slurry of glutathione-Sepharose 4B (Amersham Biosciences). The beads were washed and resuspended in 50 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM dithiothreitol, 5% glycerol, and 1 µg/ml leupeptin until use. Control experiments were performed with GST-Sepharose beads generated by expression of the empty pGEX-4T vector. Total GST fusion protein amounts were estimated visually using Coomassie Blue-stained SDS-PAGE with albumin standards. 1 mg of total protein from the appropriate mIMCD-3 whole cell lysates was then incubated with the GST fusion protein of interest for 30 min at 4 °C. The glutathione beads were washed three times with ice-cold lysis buffer followed by resolution through SDS-PAGE. Proteins were electrophoretically transferred onto Immobilon-P transfer membranes (Millipore) using Trans-Blot SD semi-dry transfer cell (Bio-Rad) for 90 min at 18 volts. Usually, membranes were blocked for 1 h at room temperature with 5% nonfat dry milk in wash buffer containing 10 mM Tris, pH 7.5, 100 mM NaCl, and 0.1% Tween 20 (TBS-T). After five additional rinses with TBS-T, blots were incubated with the appropriate primary antibody (Gab1 or p85, Upstate Biotechnology). After rinsing with TBS-T, membranes were incubated with horseradish peroxidase-conjugated secondary antibody at 1:5000 dilution in TBS-T for 60 min at room temperature. Blots were visualized by ECL system (Amersham Biosciences).

Co-immunoprecipitation and Western Blotting-- 800 µg of mIMCD-3 cell lysates were precleared for 1 h at 4 °C with protein A-Sepharose CL 4B (1:1 slurry in phosphate-buffered saline (Amersham Biosciences) and centrifuged at 5000 rpm for 2 min at 4 °C. Supernatants were incubated with anti-Gab1 overnight followed by the addition of protein A-Sepharose CL4B. After incubating for another 2 h at 4 °C, samples were centrifuged at 5000 rpm for 2 min at 4 °C and washed three times with 0.5 ml of ice-cold lysis buffer prior to the resolution through SDS-PAGE. Western blot was performed using the methods mentioned above or following the protocol of the primary antibody manufacturer. For the expression of the MBD domain of Gab1, lysates from mIMCD-3 cells transiently transfected with FLAG-MBD or vector control were used. Transfections were performed with LipofectAMINE 2000 (Invitrogen) as described previously (7, 12). Lysates were immunoprecipitated with anti-FLAG antibody (Sigma) as noted above.

For the expression of SHP2, HEK cells were transiently transfected with either the empty control vector, pIRES-GFP, or the vector encoding Myc-tagged wild-type SHP2 (SHP2-WT) or catalytically inactive SHP2 (SHP2-CS). These constructs, which independently express green fluorescent protein to allow rapid determination of transfection efficiency, were a kind gift of Dr. Anton Bennett. Cells were transfected using calcium phosphate as previously described HGF (12).

Gab1-associated PI3K Activity Assay-- Immunoprecipitation of Gab1 from control and EGF-stimulated mIMCD-3 cells ± U0126 was performed as above. Immunoprecipitates were collected by centrifugation and washed twice with phosphate-buffered saline containing 1% Nonidet P-40 and 100 µM Na3VO4, twice with 100 mM Tris, 500 mM LiCl2, 100 µM Na3VO4, pH 7.5, and twice with 10 mM Tris, 100 mM NaCl, 1 mM EDTA, and 100 µM Na3VO4, pH 7.5. The pellets were then resuspended in 50 µl of the final wash buffer containing 12 mM MgCl2 and 20 µg of phosphatidylinositol (Avanti Polar Lipids, Inc.). To start the PI3K reaction, 10 µl of 40 µM ATP containing 30 µCi of [32P]ATP was added to each pellet and was allowed to incubate at room temperature for 10 min. The reaction was stopped by the addition of 20 µl of 8 M HCl and the lipids extracted using 160 µl of CHCl3:MeOH (1:1). The phases were separated by centrifugation, and 50 µl of the lower organic phase was spotted onto a glass-backed silicon thin-layer chromatography plate. The lipids were resolved by thin-layer chromatography in MeOH-CHCl3-H2O-NH4OH (60:47:11.3:2) and visualized using the Storm PhosphorImager. Quantitation was performed on triplicate samples using ImageQuant software.

Statistical Analysis-- All experiments were repeated on at least three separate occasions. Quantification of ECL immunoblots was performed using the NIH Image program. The values for co-immunoprecipitation experiments were normalized to the amount of immunoprecipitated protein and expressed as the mean ± S.E. The results were analyzed using the Student's t test. A value of p < 0.05 was considered significant.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

EGF-dependent ERK Activation Decreases EGF-stimulated Gab1/PI3K Association-- Our observation that HGF and EGF appear to use different ERK signaling pathways for epithelial morphogenesis (18) led us to examine the effect of ERK activation on EGF-stimulated Gab1/PI3K association. Initial experiments tested the ability of a bacterially expressed GST fusion protein encoding the full-length p85 subunit of the PI3K to associate with Gab1 from EGF-stimulated mIMCD-3 cell lysates. Similar to previous results in Madin-Darby canine kidney cells (5), EGF stimulation was found to induce the interaction of Gab1 and p85 in vitro (Fig. 1A, upper panel). To examine the role of ERK in regulating this association, cells were pretreated with 10 µM U0126, a concentration of the MEK inhibitor that prevents both ERK1/2 and ERK5 activation (18). Inhibition of ERK activation resulted in a marked increase in the EGF-stimulated association of p85 with Gab1. To determine whether this effect was specific for the p85 SH2 domain interactions with Gab1, we used GST fusion proteins encoding the N-terminal SH2 and C-terminal SH2 domains of p85. These pull-down experiments revealed that the EGF-stimulated interaction of Gab1 and the N-terminal SH2 domain of p85 appears to be ERK activation-independent (Fig. 1A, middle panel), whereas the association of the C-terminal SH2 domain of p85 with Gab1 increased with the inhibition of ERK activation (Fig. 1A, lower panel), mimicking the results obtained with full-length p85.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 1.   The EGF-stimulated interaction of Gab1 with p85 is up-regulated by inhibition of ERK activation. A, bacterially expressed full-length GST-p85 (gst-p85 pulldown, upper panel), N-terminal SH2 domain of p85 (gst-NSH2 pulldown, middle panel) and C-terminal SH2 domain of p85 (gst-CSH2 pulldown, lower panel) were used for pull-down experiments of control and EGF-stimulated mIMCD-3 cell lysates ± pretreatment with U0126 (10 µM). IB:alpha -Gab, immunoblotting of Gab1. B, co-immunoprecipitation of Gab1 (IB:alpha -Gab1) and p85 (IB:alpha -p85) from mIMCD-3 cells ± EGF ± U0126. IP:alpha -Gab1, immunoprecipitation of Gab1. C, quantitation of the co-immunoprecipitation of Gab1 and p85, as shown in B, normalized to 1 for EGF stimulation alone (*, p < 0.01, n = 3).

The effects of EGF-mediated ERK activation on endogenous Gab1/PI3K interactions were then examined by co-immunoprecipitation from mIMCD-3 cells. Compared with control cells, the interaction of Gab1 and the PI3K was increased following the EGF stimulation (Fig. 1B). Consistent with the in vitro pull-down results, this interaction was further increased in the setting of inhibition of ERK activation. The quantitation of the results from three experiments revealed that stimulation with EGF resulted in a 9-fold increase in Gab1/PI3K association, whereas concomitant inhibition of ERK activation led to an additional 40% increase in the Gab1/PI3K association (Fig. 1C). This result was confirmed in EGF-stimulated HEK cells (data not shown) and demonstrates that EGF-mediated ERK activation down-regulates the EGF-stimulated Gab1/PI3K association.

ERK Regulation of EGF-stimulated Gab1/PI3K Association Occurs Outside of the MBD Domain-- In contrast to the results now presented for EGF, we have previously found that HGF-mediated ERK1/2 activation causes an increase in the HGF-stimulated Gab1/PI3K association. The association of the PI3K with Gab1 occurs primarily at three consensus YXXM association sites in Gab1 (5, 11). One of these sites, 472YVPMTP479, is included in the Gab1 MBD domain and also encodes the ERK1/2 consensus phosphorylation sequence PX(S/T)P. We have shown that the MBD region is the primary target of ERK2 phosphorylation of Gab1 (12) and that dual phosphorylation of the 472YVPMTP478 motif on Tyr472 and Thr476 results in a higher affinity binding site for p85 than does phosphorylation on Tyr472 alone (7). Because inhibition of ERK activation decreases the Gab1/PI3K association as well as downstream Akt activation by ~50% (Fig. 2A, left panel) (7), it is likely that HGF-stimulated ERK2 phosphorylation at the 472YVPMTP478 site results in a physiologically relevant increase in HGF-stimulated PI3K activation.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 2.   Differential effects of HGF and EGF-mediated ERK activation on Gab1/p85 association. A, serum-starved mIMCD-3 cells were stimulated with HGF or EGF for 10 min ± pretreatment with U0126 followed by immunoprecipitation of Gab1 (IP:alpha -Gab1) and immunoblotting with anti-p85 (IB:alpha -p85, upper panel) or anti-Gab1 (IB:alpha -Gab1, lower panel). B, the FLAG-tagged MBD of Gab1 (FLAG-MBD) and empty FLAG-CMV-II vector (Vector) were transiently transfected into mIMCD-3 cells followed by stimulation with HGF or EGF ± pretreatment with U0126. Lysates were immunoprecipitated with anti-FLAG (IP:alpha -FLAG) and immunoblotted with anti-p85 (IB:alpha -p85, upper panel). Equal expression of the FLAG-MBD construct was determined by immunoblotting 20 µg of the original cell lysate with anti-FLAG (IB:alpha -FLAG, lower panel).

The current experiments demonstrate that preventing EGF-stimulated ERK activation results in an increase in the association of Gab1 with p85, suggesting that HGF and EGF-stimulated ERK activation can mediate divergent downstream events (Fig. 2A, right panel). To determine whether the effects of EGF on ERK-regulated Gab1/PI3K association are also mediated by the MBD of Gab1, we examined the association of the MBD with p85 following HGF or EGF stimulation. The MBD of Gab1 can associate with and be phosphorylated by either the c-met receptor (directly through the c-met binding sequence and indirectly through association with Grb2) or the EGFR (indirectly through association with Grb2).

Immunoprecipitation of the epitope-tagged MBD domain reveals that both HGF and EGF can induce the association of the Gab1 MBD with the p85 subunit of the PI3K (Fig. 2B, lanes 3 and 5). In agreement with our previous finding that HGF-stimulated ERK1/2 activation results in the creation of a higher affinity p85 binding site, U0126 treatment caused a decrease in the HGF-stimulated MBD-p85 association that was indistinguishable from that seen with full-length Gab1 (Fig. 2, compare A, lanes 3 and 4, with B, lanes 3 and 4). However, the inhibition of ERK activation did not influence EGF-induced p85 binding to the Gab1 MBD (Fig. 2B, lanes 5 and 6). Interestingly, the HGF-stimulated association of p85 with the Gab1 MBD was significantly stronger than that observed for EGF stimulation, possibly because the dual binding interaction between the MBD and c-met results in a more efficient tyrosine phosphorylation of the p85 binding motif. Taken together, these results are most consistent with a model in which HGF-mediated ERK2 activation increases the Gab1/PI3K association through direct phosphorylation of the p85 binding site in the MBD, whereas EGF-mediated ERK activation decreases the Gab1/PI3K association through a mechanism outside of the MBD.

ERK Activation Decreases EGF-mediated Gab1 Tyrosine Phosphorylation-- Because p85 association is dependent on the phosphorylation of the YXXM SH2 binding sites in Gab1, the tyrosine phosphorylation state of Gab1 in both resting and EGF-stimulated mIMCD-3 cells was examined. Immunoprecipitation with anti-phosphotyrosine followed by blotting with anti-Gab1 revealed the expected increase in tyrosine phosphorylation of Gab1 following EGF stimulation with a further increase in the setting of concomitant inhibition of ERK activation (Fig. 3A).


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 3.   Effects of ERK inhibition on the EGF-induced tyrosine phosphorylation of Gab1. A, mIMCD-3 cells were stimulated with EGF ± U0126 followed by anti-phosphotyrosine immunoprecipitation (IP:alpha -pTyr) and anti-Gab1 immunoblotting (IB:alpha -Gab1, upper panel). Equal starting material for the immunoprecipitations is shown by blotting 20 µg of the original cell lysate with anti-Gab1 (IB:alpha -Gab1, lower panel). B, cells were plated in triplicate, treated ± EGF ± U0126 followed by immunoprecipitation of Gab1 (IP:alpha -Gab1) and immunoblotting with anti-phosphotyrosine (IB:alpha -pTyr, upper panel) and anti-Gab1 (IB:alpha -Gab1, lower panel). Experiment was repeated on three separate occasions, one experiment is shown. C, quantitation of the experiment, as shown in B, normalized to 1 for EGF stimulation alone (*, p < 0.001, n = 3). D, immunoprecipitation of Gab1 (IP:alpha -Gab1, upper panel) or SHP2 (IP:alpha -SHP2, lower panel) from mIMCD-3 cells stimulated with EGF ± pretreatment with U0126 followed by immunoblotting with the alternate antibody. IB:alpha -SHP2, immunoblotting of SHP2.

Immunoprecipitation of Gab1 followed by anti-phosphotyrosine immunoblotting confirmed these results (Fig. 3B) with quantitation demonstrating that inhibition of ERK activation resulted in a 62% increase in the EGF-stimulated tyrosine phosphorylation of Gab1 (Fig. 3C). In contrast, we have previously demonstrated that HGF-stimulated ERK1/2 activation does not alter c-met-mediated Gab1 tyrosine phosphorylation (7).

To investigate whether the increased Gab1 tyrosine phosphorylation, which occurs following EGF stimulation, and concomitant ERK inhibition increases the association of Gab1 with other SH2 domain-containing signaling proteins, we examined the association of Gab1 with SHP2. SHP2 is an SH2 domain-containing tyrosine phosphatase that associates with Gab1 in a phosphorylation-dependent manner at tyrosines 627 and 659 in the C terminus of Gab1 (8, 21, 22). In both anti-Gab1 and anti-SHP2 immunoprecipitates, we were able to detect the association of Gab1 with SHP2 following the stimulation of mIMCD-3 cells with EGF (Fig. 3D). After inhibition of ERK activation with U0126, there was a substantial increase in the EGF-stimulated co-immunoprecipitation of Gab1 and SHP2, similar to that seen with Gab1/PI3K association. These results demonstrate that EGFR activation in the absence of ERK activation results in a higher level of tyrosine phosphorylation of Gab1 and subsequently a greater recruitment of SH2 domain-containing proteins such as the PI3K and SHP2, and they suggest that EGF-stimulated ERK activation normally serves to down-regulate Gab1 signaling.

ERK Inhibition Does Not Alter EGFR Phosphorylation or EGFR·Grb2·Gab1 Complex Formation-- Two potential mechanisms, whereby EGF-stimulated ERK activation could decrease the tyrosine phosphorylation state of Gab1, are to either decrease the EGFR-dependent tyrosine phosphorylation of Gab1 or to increase the activity of a Gab1-associated phosphatase. A decrease in the EGFR-dependent tyrosine phosphorylation of Gab1 could occur because of the inhibition of the EGFR tyrosine kinase activity or a decrease in the association of Gab1 with the EGFR. As a marker for EGFR tyrosine kinase activity, we examined the tyrosine phosphorylation state of the EGFR after stimulation with EGF. Anti-phosphotyrosine immunoblots of anti-EGFR immunoprecipitates revealed an indistinguishable level of EGFR phosphorylation in cells stimulated with EGF in the presence or absence of ERK inhibition with U0126 (Fig. 4A).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 4.   ERK inhibition does not alter EGFR phosphorylation or EGFR·Grb2·Gab1 complex formation. mIMCD-3 cells were serum-starved overnight and then stimulated with EGF ± pretreatment with U0126. A, the EGFR was immunoprecipitated (IP:alpha -EGFR), and its phosphorylation state was determined by immunoblotting with anti-pTyr (IB:alpha -pTyr, upper panel). Equal loading was determined by stripping and re-probing the same membrane with the antibody to the EGFR (IB:alpha -EGFR, lower panel). B, Gab1·Grb2 complex formation was examined by co-immunoprecipitation of the proteins. IB:alpha -Gab1, immunoblotting of Gab1; IB:alpha -Grb2, immunoblotting of Grb2. C, cells were treated ± EGF ± U0126 followed by immunoprecipitation of Grb2 (IP:alpha -Grb2) and immunoblotting with either the anti-EGFR antibody (IB:alpha -EGFR, upper panel) or with anti-Grb2 (IB:alpha -Grb2, lower panel).

The association of Gab1 with the EGFR occurs indirectly via an SH3-mediated association of Gab1 and Grb2 and a phosphotyrosine-dependent SH2-mediated association of Grb2 with the EGFR. Because ERK2 has been shown to directly phosphorylate Gab1 in the MBD region that encodes one of the proline-rich Grb2 SH3 binding sites (11), we examined the effects of EGF-stimulated ERK activation on Gab1·Grb2 and Grb2·EGFR complex formation. The SH3-mediated association of Gab1 and Grb2 was found to be constitutive and was not altered by EGF stimulation, either in the presence or absence ERK inhibition (Fig. 4B). The SH2-mediated association of Grb2 with the EGFR was increased following EGF stimulation with no alteration detected in the setting of ERK inhibition (Fig. 4C). These results demonstrate no detectable effect of ERK activation on EGFR phosphorylation or association of the receptor with Gab1 and thus do not support the model that the EGF-stimulated ERK-dependent decrease in Gab1 tyrosine phosphorylation is the result of regulation of the EGFR-mediated tyrosine phosphorylation of Gab1.

EGF Stimulates SHP2-dependent Dephosphorylation of Gab1-- An alternative explanation for the ERK-mediated decrease in EGF-stimulated tyrosine phosphorylation of Gab1 is that ERK serves to either recruit and/or activate a tyrosine phosphatase to Gab1. To examine this possibility, we determined the tyrosine phosphorylation state of Gab1 in the presence of the cell-permeable phosphatase inhibitor pervanadate. The addition of pervanadate at 50 µM to serum-starved mIMCD-3 cells resulted in a 4-fold increase in basal Gab1 tyrosine phosphorylation (Fig. 5A, quantitated in B). Stimulation with EGF increased the level of tyrosine phosphorylation 9-fold over base line with an additional 2.2-fold increase in phosphorylation in the setting of pervanadate treatment. These data demonstrate that one or more phosphatases regulate the tyrosine phosphorylation state of Gab1 both in quiescent and EGF-stimulated cells.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 5.   Phosphatase-mediated dephosphorylation of Gab1. A, after overnight serum starvation, mIMCD-3 cells were stimulated with EGF ± pretreatment with pervanadate (50 µM). Phosphorylation of Gab1 was determined by anti-Gab1 immunoprecipitation (IP:alpha -Gab1) followed by immunoblotting with anti-pTyr (IB:alpha -pTyr). IB:alpha -Gab1, immunoblotting of Gab1. B, quantitation of these experiments was performed normalized to 1 for EGF stimulation alone (*, p < 0.01 versus no pervanadate, n = 3). C, either Myc-tagged SHP2-WT, SHP2-CS, or the empty vector was transiently expressed in HEK cells. The cells were serum-starved for 6 h followed by stimulation with EGF or vehicle control. Phosphorylation of Gab1 was determined by anti-pTyr immunoblotting (IB:alpha -pTyr) of anti-Gab1 immunoprecipitates (IP:alpha -Gab1) (upper panel). Equal loading was determined by re-probing the same membrane with anti-Gab1 (IB:alpha -Gab1, middle panel). Equal expression of the Myc-tagged constructs was determined by immunoblotting whole cell lysates with an anti-Myc antibody (IB:alpha -Myc, lower panel).

A logical candidate for an EGF-dependent ERK-stimulated Gab1 tyrosine phosphatase is SHP2. Recently, Gab1 has been identified as a potential SHP2 substrate in the EGF (8) and cytokine receptor signaling pathways (10). In the work by Cunnick et al. (8), SHP2 was found to be capable of dephosphorylating peptides containing either phosphorylated Tyr589 (a PI3K binding site in Gab1) or Tyr627 + Tyr659 (the SHP2 binding sites in Gab1), although the ability of SHP2 to dephosphorylate native Gab1 following EGF stimulation was not determined. To further examine the role of SHP2 in Gab1 dephosphorylation, we used the transient expression of SHP2-CS in HEK cells. In unstimulated cells, the expression of SHP2-CS resulted in a minimal increase in the tyrosine phosphorylation of Gab1 as compared with cells expressing wild-type SHP2 or the empty vector (Fig. 5C, lane 2 versus lanes 1 and 3). However, following EGF stimulation, SHP2-CS-expressing cells exhibited approximately a 2-fold increase in tyrosine phosphorylation compared with controls, a change similar to that seen following pervanadate treatment (Fig. 5A) or U0126 treatment (Fig. 3B). Of note, we have thus far been unable to detect an increase in SHP2 phosphatase activity in Gab1 immunoprecipitates from EGF-stimulated cells using the artificial substrate paranitrophenyl phosphate, preventing us from directly determining the role of ERK activation in the regulation of SHP2. Based on the results shown in Fig. 5A, we believe that this failure to detect increased SHP2 activity is because of either the relative insensitivity of the assay or the instability of the Gab1/SHP2 association.

Our present data are most consistent with a model in which EGF stimulation results in tyrosine phosphorylation of Gab1 followed by recruitment of the PI3K and SHP2. SHP2 then acts to dephosphorylate Gab1 and down-regulate its activation, an effect that is enhanced by simultaneous ERK activation. ERK could be acting to either increase the association of Gab1 with SHP2 or to stimulate its phosphatase activity. Our observation that inhibition of ERK activation results in an increase in the association of Gab1 with SHP2 (Fig. 3D) would seem to rule out the former possibility. However, it is conceivable that an initial ERK-mediated increase in SHP2 association results in the dephosphorylation of multiple Gab1 tyrosine residues including Tyr627 and/or Tyr659 followed by the loss of the SHP2-Gab1 association. Interestingly, the association of SHP2 with Gab1 through Tyr627 and Tyr659 has been found to be required for EGF-induced ERK2 activation (8, 22), suggesting that the ERK-mediated decrease in tyrosine phosphorylation of Gab1 might then serve as a negative feedback regulator of further ERK2 activation.

ERK Regulates EGF-stimulated PI3K Activity and Akt Activation-- The binding of the p85 subunit of the PI3K to phosphotyrosine residues typically results in the activation of the catalytic 110kD subunit of the enzyme and the production of phosphoinositide 3,4,5 triphosphate (PI-3,4,5-P3) at the cell membrane. To determine whether the increase in the PI3K-Gab1 association detected following the inhibition of ERK activation plays a significant role in the activation state of the PI3K, PI3K activity was assayed in anti-Gab1 immunoprecipitates from EGF-stimulated cells. The stimulation of mIMCD-3 cells with EGF increased the activity of the PI3K by ~1.5-fold (Fig. 6A). The pretreatment of EGF-stimulated cells with U0126 resulted in an additional 2-fold increase in Gab1-associated PI3K activity.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 6.   ERK regulates EGF-stimulated PI3K activity. A, PI3K activity was measured in anti-Gab1 immunoprecipitates from mIMCD-3 cells stimulated with EGF ± U0126. Incorporation of 32P-labeled phosphate into phosphatidylinositol to form phosphatidylinositol 3-phosphate (PI3P) was detected by autoradiography (upper panel) and quantitated (lower panel), normalized to 1 for control (*, p < 0.001, n = 3). B, serum-starved mIMCD-3 cells were stimulated with EGF ± U0126. Twenty micrograms of whole cell lysates were separated by SDS-PAGE and were analyzed by anti-phospho-Akt (IB:alpha -p-Akt, upper panel), anti-phospho-ERK (IB:alpha -p-ERK, middle panel), and anti-total Akt (IB:alpha -Akt, lower panel). C, the quantitation of three experiments performed as described in B (*, p < 0.01, n = 3,).

The production of PI-3,4,5-P3 at the membrane serves as a binding site for PH domain containing proteins such as Akt. The recruitment of Akt to the cell membrane results in its phosphorylation and activation by protein kinase B, leading to enhanced cell survival and proliferation (23). To determine whether ERK regulates the activation of this signaling pathway downstream of the PI3K, we examined the activation of Akt using a phosphorylation-specific antibody. Akt was basally phosphorylated to a low level in control cells with a 1-fold increase in Akt activation following EGF stimulation (Fig. 6B, quantitated in C). Although U0126 pretreatment had no effect on basal Akt phosphorylation, EGF-stimulated cells demonstrated a further 50% increase in Akt phosphorylation in the setting of U0126-mediated ERK inhibition. These results demonstrate that EGF-stimulated ERK activation plays a significant role in down-regulating the ability of Gab1 to recruit and activate the PI3K and its downstream effectors.

Although both HGF and EGF are capable of activating Gab1 and inducing epithelial morphogenesis, the phenotypic effects of these growth factors are distinct. HGF stimulation of mIMCD-3 cells results in cell processes with multiple branches, whereas the EGFR ligands EGF and transforming growth factor-alpha stimulate longer processes with fewer branch points (24). The ability of Gab1 to induce these morphogenic effects is dependent on its localization to the membrane, which is mediated by the binding of the Gab1 PH domain to PI-3,4,5-P3 (5). The association of the PI3K with Gab1, resulting in local PI-3,4,5-P3 generation, thus serves to perpetuate Gab1 signaling. Therefore, the careful regulation of this interaction may serve to dictate whether the phenotypic outcome of receptor stimulation is process branching or process elongation.

Our results suggest that growth factor-selective MAPK activation is capable of providing a second level of regulation of the interaction of the PI3K and Gab1 in addition to receptor phosphorylation of the p85 binding sites. HGF-activated ERK2 appears to directly phosphorylate Gab1 near the p85 binding site, resulting in enhanced PI3K binding and activation. In contrast, EGF-stimulated ERK activation, possibly ERK5, causes a decrease in the tyrosine phosphorylation state of Gab1 and results in diminished PI3K signaling.

    ACKNOWLEDGEMENTS

We thank Lucia Rameh for the GST-p85 fusion protein constructs and Anton Bennett and Maria Kontaridis for the SHP2 constructs.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant DK54911 (to L. G. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Internal Medicine, Section of Nephrology, Yale University School of Medicine, 333 Cedar St., LMP 2093, New Haven, CT 06520-8062. Tel.: 203-785-7111; Fax: 203-785-7068; E-mail: chengfang.yu@yale.edu.

Published, JBC Papers in Press, March 14, 2002, DOI 10.1074/jbc.M200732200

    ABBREVIATIONS

The abbreviations used are: Gab1, Grb2-associated binder-1; EGF, epidermal growth factor; EGFR, EGF receptor; PH, pleckstrin homology; PI3K, phosphatidylinositol 3-kinase; SH, Src homology; MAPK, mitogen-activated protein kinase; PI-3, 4,5-P3, phosphatidylinositol 3,4,5-trisphosphate; HEK, human embryonic kidney; TBS-T, Tris-buffered saline with Tween 20; GST, glutathione S-transferase; ERK, extracellular signal-regulated kinase; MEK, MAPK/extracellular signal-regulated kinase kinase; SHP2-WT, wild-type SHP2; SHP-CS, catalytically inactive SHP2; HGF, hepatocyte growth factor.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

1. Weidner, K. M., Di, Cesare, S., Sachs, M., Brinkmann, V., Behrens, J., and Birchmeier, W. (1996) Nature 384, 173-176[CrossRef][Medline] [Order article via Infotrieve]
2. Holgado-Madruga, M., Emlet, D. R., Moscatello, D. K., Godwin, A. K., and Wong, A. J. (1996) Nature 379, 560-564[CrossRef][Medline] [Order article via Infotrieve]
3. Kameda, H., Risinger, J. I., Han, B. B., Baek, S. J., Barrett, J. C., Abe, T., Takeuchi, T., Glasgow, W. C., and Eling, T. E. (2001) Mol. Cell. Biol. 21, 6895-6905[Abstract/Free Full Text]
4. Korhonen, J. M., Said, F. A., Wong, A. J., and Kaplan, D. R. (1999) J. Biol. Chem. 274, 37307-37314[Abstract/Free Full Text]
5. Maroun, C. R., Holgado-Madruga, M., Royal, I., Naujokas, M. A., Fournier, T. M., Wong, A. J., and Park, M. (1999) Mol. Cell. Biol. 19, 1784-1799[Abstract/Free Full Text]
6. Fixman, E. D., Holgado-Madruga, M., Nguyen, L., Kamikura, D. M., Fournier, T. M., Wong, A. J., and Park, M. (1997) J. Biol. Chem. 272, 20167-20172[Abstract/Free Full Text]
7. Yu, C. F., Roshan, B., Liu, Z. X., and Cantley, L. G. (2001) J. Biol. Chem. 276, 32552-32558[Abstract/Free Full Text]
8. Cunnick, J. M., Mei, L., Doupnik, C. A., and Wu, J. (2001) J. Biol. Chem. 276, 24380-24387[Abstract/Free Full Text]
9. Takahashi-Tezuka, M., Yoshida, Y., Fukada, T., Ohtani, T., Yamanaka, Y., Nishida, K., Nakajima, K., Hibi, M., and Hirano, T. (1998) Mol. Cell. Biol. 18, 4109-4117[Abstract/Free Full Text]
10. Nishida, K., Yoshida, Y., Itoh, M., Fukada, T., Ohtani, T., Shirogane, T., Atsumi, T., Takahashi-Tezuka, M., Ishihara, K., Hibi, M., and Hirano, T. (1999) Blood 93, 1809-1816[Abstract/Free Full Text]
11. Schaeper, U., Gehring, N. H., Fuchs, K. P., Sachs, M., Kempkes, B., and Birchmeier, W. (2000) J. Cell Biol. 149, 1419-1432[Abstract/Free Full Text]
12. Roshan, B., Kjelsberg, C., Spokes, K., Eldred, A., Crovello, C. S., and Cantley, L. G. (1999) J. Biol. Chem. 274, 36362-36368[Abstract/Free Full Text]
13. Frevert, E. U., Bjorbaek, C., Venable, C. L., Keller, S. R., and Kahn, B. B. (1998) J. Biol. Chem. 273, 25480-25487[Abstract/Free Full Text]
14. Kimura, K., Hattori, S., Kabuyama, Y., Shizawa, Y., Takayanagi, J., Nakamura, S., Toki, S., Matsuda, Y., Onodera, K., and Fukui, Y. (1994) J. Biol. Chem. 269, 18961-18967[Abstract/Free Full Text]
15. Leevers, S. J., Weinkove, D., MacDougall, L. K., Hafen, E., and Waterfield, M. D. (1996) EMBO J. 15, 6584-6594[Medline] [Order article via Infotrieve]
16. Derman, M. P., Cunha, M. J., Barros, E. J., Nigam, S. K., and Cantley, L. G. (1995) Am. J. Physiol. 268, F1211-F1217[Medline] [Order article via Infotrieve]
17. Fan, S., Ma, Y. X., Gao, M., Yuan, R. Q., Meng, Q., Goldberg, I. D., and Rosen, E. M. (2001) Mol. Cell. Biol. 21, 4968-4984[Abstract/Free Full Text]
18. Karihaloo, A., O'Rourke, D. A., Nickel, C., Spokes, K., and Cantley, L. G. (2001) J. Biol. Chem. 276, 9166-9173[Abstract/Free Full Text]
19. Rauchman, M., Nigam, S., Delpire, E., and Gullans, S. (1993) Am. J. Physiol. 265, F416-F424[Medline] [Order article via Infotrieve]
20. Davies, S. P., Reddy, H., Caivano, M., and Cohen, P. (2000) Biochem. J. 351, 95-105[CrossRef][Medline] [Order article via Infotrieve]
21. Yart, A., Laffargue, M., Mayeux, P., Chretien, S., Peres, C., Tonks, N., Roche, S., Payrastre, B., Chap, H., and Raynal, P. (2001) J. Biol. Chem. 276, 8856-8864[Abstract/Free Full Text]
22. Cunnick, J. M., Dorsey, J. F., Munoz-Antonia, T., Mei, L., and Wu, J. (2000) J. Biol. Chem. 275, 13842-13848[Abstract/Free Full Text]
23. Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P., and Hemmings, B. A. (1996) EMBO J. 15, 6541-6551[Medline] [Order article via Infotrieve]
24. Barros, E. J., Santos, O. F., Matsumoto, K., Nakamura, T., and Nigam, S. K. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 4412-4416[Abstract/Free Full Text]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
A. Kiyatkin, E. Aksamitiene, N. I. Markevich, N. M. Borisov, J. B. Hoek, and B. N. Kholodenko
Scaffolding Protein Grb2-associated Binder 1 Sustains Epidermal Growth Factor-induced Mitogenic and Survival Signaling by Multiple Positive Feedback Loops
J. Biol. Chem., July 21, 2006; 281(29): 19925 - 19938.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. Y. Lee, E. J. Kang, G. Y. Hur, K. H. Jung, H. C. Jung, S. Y. Lee, J. H. Kim, C. Shin, K. H. In, K. H. Kang, et al.
Peroxisome proliferator-activated receptor-{gamma} inhibits cigarette smoke solution-induced mucin production in human airway epithelial (NCI-H292) cells
Am J Physiol Lung Cell Mol Physiol, July 1, 2006; 291(1): L84 - L90.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
G. Sithanandam, G. T. Smith, J. R. Fields, L. W. Fornwald, and L. M. Anderson
Alternate Paths from Epidermal Growth Factor Receptor to Akt in Malignant Versus Nontransformed Lung Epithelial Cells: ErbB3 Versus Gab1
Am. J. Respir. Cell Mol. Biol., November 1, 2005; 33(5): 490 - 499.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Gallicchio, S. Mitola, D. Valdembri, R. Fantozzi, B. Varnum, G. C. Avanzi, and F. Bussolino
Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor
Blood, March 1, 2005; 105(5): 1970 - 1976.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Arnaud, C. Crouin, C. Deon, D. Loyaux, and J. Bertoglio
Phosphorylation of Grb2-Associated Binder 2 on Serine 623 by ERK MAPK Regulates Its Association with the Phosphatase SHP-2 and Decreases STAT5 Activation
J. Immunol., September 15, 2004; 173(6): 3962 - 3971.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Holgado-Madruga and A. J. Wong
Role of the Grb2-Associated Binder 1/SHP-2 Interaction in Cell Growth and Transformation
Cancer Res., March 15, 2004; 64(6): 2007 - 2015.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
G. S. Kapoor, Y. Zhan, G. R. Johnson, and D. M. O'Rourke
Distinct Domains in the SHP-2 Phosphatase Differentially Regulate Epidermal Growth Factor Receptor/NF-{kappa}B Activation through Gab1 in Glioblastoma Cells
Mol. Cell. Biol., January 15, 2004; 24(2): 823 - 836.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
N. C. Sundgren, G. D. Giraud, J. M. Schultz, M. R. Lasarev, P. J. S. Stork, and K. L. Thornburg
Extracellular signal-regulated kinase and phosphoinositol-3 kinase mediate IGF-1 induced proliferation of fetal sheep cardiomyocytes
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2003; 285(6): R1481 - R1489.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Macdonald, K. Crowder, A. Street, C. McCormick, K. Saksela, and M. Harris
The Hepatitis C Virus Non-structural NS5A Protein Inhibits Activating Protein-1 Function by Perturbing Ras-ERK Pathway Signaling
J. Biol. Chem., May 9, 2003; 278(20): 17775 - 17784.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Martinez and F. C. A. Gomes
Neuritogenesis Induced by Thyroid Hormone-treated Astrocytes Is Mediated by Epidermal Growth Factor/Mitogen-activated Protein Kinase-Phosphatidylinositol 3-Kinase Pathways and Involves Modulation of Extracellular Matrix Proteins
J. Biol. Chem., December 13, 2002; 277(51): 49311 - 49318.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
T. Cai, K. Nishida, T. Hirano, and P. A. Khavari
Gab1 and SHP-2 promote Ras/MAPK regulation of epidermal growth and differentiation
J. Cell Biol., October 14, 2002; 159(1): 103 - 112.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/22/19382    most recent
M200732200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow